The brenipatide Phase 3 program is Lilly’s bet that it can reach an alcohol and depression label before anyone else, and it pulls a possible approval years closer. Key Points Lilly sent brenipatide, an experimental GIP/GLP-1 drug, straight from Phase 1 into Phase 3 for alcohol use disorder and major depression, skipping the mid-stage trial
Only USPSTF grades A and B must be covered by most insurance plans at no cost. What that means for PSA tests and calcium scans, and why both are stuck.
Cancer risk by age, for men, with smoking, weight and alcohol toggles: out of 10,000 U.S. men aged 50, about 145 die of cancer within ten years. Prostate tops the list of cancers men get at 50, 60, 70 and 80 (excluding common skin cancers), and reaches the top two of the list that kills only at 70 and 80.
Updated September 24, 2026 with the NHS-Galleri paper and the FDA panel vote. The deadliest cancers for men over 50, by age band; what half a century of progress actually bought; and the one screening decision where three expert bodies still disagree. By Gunnar · Not medical advice · Every number links to its source
A hacked small-town government website is ranking on Google for real peptide brands and redirecting searchers into a WhatsApp sales operation.
Updated September 26, 2026 with Lilly’s first Phase 1 safety data and a note that the drug is dosed weekly, not monthly. Brenipatide side effects: thirteen registered trials, ten conditions, and not one has reported. Here is what is actually known. I take tirzepatide every Friday, so I know exactly what a GLP-1 does to
My calcium score is zero and my ApoB was flagged high. When the 2026 guideline lets a zero defer a statin, the four exceptions, how long a zero lasts, and what I did.
I read the study behind the alcohol and cancer deaths headlines. Since 1990, the national rate rose modestly — men 55 and older saw by far the sharpest increase.
Both machines live in my garage. With a bone-on-bone knee, the bike gets most of the work, even though the one implant study that measured both found less knee force on the rower.
Pelacarsen missed its primary endpoint in the Lp(a)HORIZON trial. Here’s what’s actually known, what two doctors think happened, and why I’m putting my own effort back into LDL and ApoB instead of waiting on an Lp(a) drug.
